2021
DOI: 10.1093/bib/bbab109
|View full text |Cite
|
Sign up to set email alerts
|

An effective self-supervised framework for learning expressive molecular global representations to drug discovery

Abstract: How to produce expressive molecular representations is a fundamental challenge in artificial intelligence-driven drug discovery. Graph neural network (GNN) has emerged as a powerful technique for modeling molecular data. However, previous supervised approaches usually suffer from the scarcity of labeled data and poor generalization capability. Here, we propose a novel molecular pre-training graph-based deep learning framework, named MPG, that learns molecular representations from large-scale unlabeled molecule… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
117
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
5
2
2

Relationship

0
9

Authors

Journals

citations
Cited by 95 publications
(117 citation statements)
references
References 34 publications
0
117
0
Order By: Relevance
“…De novo drug design (Hartenfeller and Schneider, 2010) through existing computer technology can speed up drug development and save research costs. The tasks involved in de novo drug design include molecular generation (Gómez-Bombarelli et al, 2016;Cao and Kipf, 2018;Jin et al, 2018;You et al, 2018;Madhawa et al, 2019;Popova et al, 2019;Zhang et al, 2019;Hong et al, 2020;Zang and Wang, 2020;Bagal et al, 2021), drug and drug interactions (DDI) (Li et al, 2021;Lin et al, 2021;Lyu et al, 2021;Zhao et al, 2021), disease associations (Ding et al, 2020;Lei and Zhang, 2020;Mudiyanselage et al, 2020;Lei X.-J. et al, 2021;Lei X. et al, 2021;Wang Y. et al, 2021;Lei and Zhang, 2021;Yang and Lei, 2021;Zhang et al, 2021), and so on.…”
Section: Introductionmentioning
confidence: 99%
“…De novo drug design (Hartenfeller and Schneider, 2010) through existing computer technology can speed up drug development and save research costs. The tasks involved in de novo drug design include molecular generation (Gómez-Bombarelli et al, 2016;Cao and Kipf, 2018;Jin et al, 2018;You et al, 2018;Madhawa et al, 2019;Popova et al, 2019;Zhang et al, 2019;Hong et al, 2020;Zang and Wang, 2020;Bagal et al, 2021), drug and drug interactions (DDI) (Li et al, 2021;Lin et al, 2021;Lyu et al, 2021;Zhao et al, 2021), disease associations (Ding et al, 2020;Lei and Zhang, 2020;Mudiyanselage et al, 2020;Lei X.-J. et al, 2021;Lei X. et al, 2021;Wang Y. et al, 2021;Lei and Zhang, 2021;Yang and Lei, 2021;Zhang et al, 2021), and so on.…”
Section: Introductionmentioning
confidence: 99%
“…As the scaffold represents the core structure of a compound, our results indicate that the model trained with MTL captures more inherent characteristics via sharing knowledge across multiple tasks. By MTL, the learned model achieves a similar effect of representation learning by self-supervised learning [37]. Thus the high-quality representation learned by MTL leads to greater predictive power compared to single-task learning.…”
Section: Results On Drug-target Affinity Predictionmentioning
confidence: 97%
“…The similar idea could also be applied to drug development. However, existing methods proposed to design (or generate) novel drug candidates neglected to consider either the 3-D structures or the protein-drug interactions [58,59,60,61,62,63,64,65,66]. Here, we suggest that LigPose has the potential to build novel end-to-end drug-generation methods with both reőned structural details and conődent bioactivity prediction, to boost de novo drug design, which can be regarded as the future work.…”
Section: Discussionmentioning
confidence: 99%